Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ia/Ib and Potential Phase IIa Study of the Safety and Pharmacokinetics of NOX66 Both as a Monotherapy and in Combination With Carboplatin in Patients With Refractory Solid Tumours

Trial Profile

Phase Ia/Ib and Potential Phase IIa Study of the Safety and Pharmacokinetics of NOX66 Both as a Monotherapy and in Combination With Carboplatin in Patients With Refractory Solid Tumours

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 Jun 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Idronoxil (Primary) ; Carboplatin
  • Indications Advanced breast cancer; Head and neck cancer; Lung cancer; Ovarian cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms CEP-1
  • Sponsors Noxopharm
  • Most Recent Events

    • 30 May 2021 Status changed from active, no longer recruiting to completed.
    • 10 Apr 2019 According to a Noxopharm media release, this study enrolled 19 patients with late-stage metastatic, solid cancers (breast, lung, ovarian, prostate).
    • 29 Nov 2018 According to a Noxopharm media release, data from phase 1b portion of the this study were presented at the Clinical Oncology Society of Australia (COSA) Annual Meeting (Nov 2018).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top